SECOND OPINIONS FOR
PAEDIATRIC CANCERS: INDIA & CHINA
Children's cancers are not smaller versions of adult cancers — they are biologically distinct diseases that demand subspecialist paediatric oncology expertise. The right second opinion can be the difference between cure and chronic toxicity.
analyticsAt a Glance
- check_circlePaediatric oncology second opinions change treatment plans in up to 40% of cases — higher than for adult cancers
- check_circleMolecular subgroup testing (medulloblastoma, ALL risk stratification, neuroblastoma MYCN) is frequently incomplete at non-specialist centres
- check_circleIndia's KDAH (Tata Memorial), CMC Vellore, and Apollo Hospitals offer internationally accessible paediatric oncology expertise
- check_circleChina's PKUPH and Fudan Children's Hospital offer paediatric haematology and oncology including CAR-T and haploidentical transplant access
Why Second Opinions Matter More in Paediatric Oncology
Childhood cancers are rare — a paediatrician or general oncologist may see one or two cases of retinoblastoma, Wilms tumour, or medulloblastoma in their entire career. The diagnosis, risk stratification, treatment protocol selection, and long-term toxicity management of paediatric cancers require dedicated paediatric oncology expertise that is simply not available outside specialist centres. The consequences of under-treating or over-treating a childhood cancer — both for survival and for lifelong function — are measured in decades.
“In paediatric oncology, the right treatment protocol is the difference between an 80% cure rate and a 50% cure rate — and between a child who grows normally and one who carries the late effects of over-treatment for life.”
Molecular Subgroup Testing Is Frequently Incomplete
Medulloblastoma molecular subgroup (WNT/SHH/Group 3/Group 4) determines treatment intensity — but many community hospitals do not perform DNA methylation profiling or the full molecular panel required for correct subgroup classification. Treatment stratified on histology alone without molecular subgroup is now considered below standard of care.
Long-Term Toxicity Planning Requires Specialist Input
Craniospinal irradiation causes IQ decline; cisplatin causes hearing loss; anthracyclines cause cardiac toxicity; high-dose steroids affect growth. Minimising these late effects while preserving cure rates requires access to proton therapy, ototoxicity monitoring protocols, and dose-modified regimens developed by cooperative group trials — available only at specialist paediatric centres.
Leading Paediatric Oncology Centres in India and China
These centres offer the paediatric oncology subspecialist depth, molecular diagnostic infrastructure, and international patient access that make them the most appropriate second opinion destinations for childhood cancer cases.
| Centre | Location | Paediatric Oncology Strengths | International Access |
|---|---|---|---|
| KDAH (Kalpana Chawla Division of Paediatric Oncology), Tata Memorial | Mumbai, India | India's largest and most experienced paediatric cancer unit; ALL, medulloblastoma, Wilms, retinoblastoma, neuroblastoma, sarcoma; BMT programme | International patients via TMC International Cell; CancerFax facilitates referrals |
| Christian Medical College (CMC) | Vellore, Tamil Nadu | Particularly strong in haematological malignancies (ALL, AML); BMT programme with haploidentical capability; paediatric solid tumours | Strong regional draw from South Asia; English-language care; established international referral pathway |
| Apollo Proton Cancer Centre / Apollo Children's | Chennai, Tamil Nadu | India's only paediatric proton therapy programme; medulloblastoma, low-grade glioma, ependymoma, sarcoma | JCI-accredited international patient infrastructure; best in India for paediatric proton therapy second opinion |
| AIIMS New Delhi | New Delhi | Strong paediatric haematology (ALL, AML); solid tumour programme; cooperative group trial access | Government hospital — lower cost; CancerFax facilitates international access |
| Peking University People's Hospital (PKUPH) | Beijing, China | Asia's largest paediatric ALL and haploidentical transplant programme; CAR-T for paediatric r/r ALL; AML and aplastic anaemia | CancerFax manages full process; Peking Protocol haploidentical transplant is world-leading |
| Fudan University Children's Hospital | Shanghai, China | Strong paediatric haematology, solid tumours, neuroblastoma; molecular subgroup testing; NMPA-approved CAR-T access | CancerFax facilitates; English report available through CancerFax coordinator |
| Children's Hospital of Fudan (CHFU) | Shanghai, China | Neuroblastoma, Wilms tumour, hepatoblastoma, paediatric sarcoma; solid tumour subspeciality depth | CancerFax facilitates; growing international patient programme |
Paediatric Cancer Second Opinion: Most Valuable Scenarios by Diagnosis
These are the paediatric diagnoses where specialist second opinion most commonly changes management — based on molecular testing gaps, treatment intensity decisions, and specialist technique requirements.
| Diagnosis | Why Second Opinion Is High Value | What Often Changes |
|---|---|---|
| Medulloblastoma | Molecular subgroup (WNT/SHH/Group 3/4) not tested — determines whether treatment can be de-escalated or must be intensified | Treatment intensity: WNT patients may avoid CSI dose escalation; Group 3 patients need intensification |
| Acute lymphoblastic leukaemia (ALL) | MRD (minimal residual disease) assessment not performed; risk stratification may be incomplete; CAR-T eligibility for r/r ALL not assessed | Treatment intensity, SCT indication, CAR-T eligibility identification |
| Neuroblastoma | MYCN amplification and INRG risk stratification may be incomplete; MIBG therapy availability not assessed locally | Risk group changes in 15–20% of cases; MIBG or DFMO access identified |
| Retinoblastoma | Laterality, group staging, and eligibility for intra-arterial chemotherapy (IAC) may not have been assessed | IAC vs systemic therapy; eye salvage rate significantly higher at specialist centre with IAC capability |
| Ependymoma | Molecular subgroup not tested; extent of resection decision critical for prognosis — requires review at high-volume neurosurgery centre | RT planning, surgical referral for incomplete resection re-operation |
| Paediatric sarcoma (EWING, osteosarcoma, RMS) | Diagnostic subtype confirmation requires subspecialist sarcoma pathology; limb salvage vs amputation requires specialist surgical review | Diagnosis changed in up to 30% at reference centres; limb salvage feasibility identified |
How CancerFax Facilitates a Paediatric Cancer Second Opinion
Paediatric oncology second opinions require specific additional documentation compared to adult cancer reviews — including molecular subgroup testing reports, growth/developmental assessments, and cooperative group protocol eligibility information.
- 1
Submit Paediatric-Specific Records
Pathology report with IHC and molecular panel; bone marrow biopsy and aspirate (for haematological malignancies); NGS myeloid or lymphoid panel; cytogenetics; MRI brain + spine where relevant; CT chest/abdomen/pelvis; any molecular subgroup or DNA methylation reports performed; birth history and current weight/height/BSA.
- 2
Identify the Specific Clinical Question',
Is this about diagnosis confirmation? Risk stratification? Treatment intensity? Late effects minimisation? Proton therapy access? CAR-T eligibility? Framing the question clearly helps CancerFax match the case to the right subspecialist.
- 3
Centre Matching and Remote Pre-Review
CancerFax identifies the most appropriate paediatric oncology centre for the specific diagnosis and clinical question — then arranges a remote pre-review to confirm the case is appropriate for the selected centre before any travel is planned.
- 4
Logistics Support for Families Travelling with a Child
Travelling internationally with an unwell child requires specific support — CancerFax assists with paediatric medical visa documentation, child-appropriate accommodation options near the hospital, and a dedicated bilingual coordinator who is experienced with paediatric cases.
- 5
Report and Cooperative Group Trial Access Assessment
The second opinion report for paediatric cases includes assessment of eligibility for open cooperative group trials (COG, SIOPE, CCLG) — often the most important component for children with rare or high-risk diagnoses.
India vs China for Paediatric Cancer Second Opinions
Both countries offer world-class paediatric oncology second opinions — the right choice depends on diagnosis, the specific clinical question, and the patient's origin and logistics.
India (KDAH / CMC / Apollo)
- English-language clinical communication throughoutIndia's paediatric oncology centres operate in English — consultations, reports, and correspondence are delivered without translation for most international patients, significantly simplifying family navigation.
- Proton therapy for paediatric CNS and solid tumoursApollo Proton Cancer Centre Chennai is the only proton therapy centre in India with a dedicated paediatric programme — critical for medulloblastoma, low-grade glioma, and ependymoma where late cognitive and endocrine effects of photon CSI are severe.
- Lower cost for self-pay patientsPaediatric oncology at Tata Memorial is government-subsidised — treatment costs are significantly lower than either Chinese private hospitals or Western centres, making it the most affordable high-quality paediatric second opinion destination.
China (PKUPH / Fudan Children's)
- Haploidentical transplant at PKUPH for children without matched donorsThe Peking Protocol for haploidentical transplantation in paediatric ALL and aplastic anaemia is world-leading — PKUPH is the destination of choice for children who need SCT but lack a matched donor.
- NMPA-approved CAR-T for paediatric r/r ALLChinese NMPA has approved CD19-directed CAR-T for paediatric relapsed/refractory ALL — Ruijin and PKUPH have the most experience. Cost is significantly lower than equivalent US/European CAR-T.
- Neuroblastoma and solid tumour specialist depth at Fudan Children'sFudan Children's Hospital has particular depth in paediatric solid tumours including neuroblastoma, hepatoblastoma, and Wilms tumour — high volumes driven by population-level incidence.
Frequently Asked Questions
Common questions from families seeking paediatric cancer second opinions internationally.
About Paediatric Cancer Second Opinions
My child has been diagnosed with ALL and given a treatment protocol — should I get a second opinion?
Yes — particularly to confirm risk stratification and MRD (minimal residual disease) monitoring is being performed to the standard required by contemporary ALL protocols. Incomplete MRD assessment means that high-risk patients are not identified for treatment intensification and transplant, while standard-risk patients may be over-treated. A paediatric haematology second opinion at KDAH, CMC Vellore, or PKUPH will confirm whether the protocol is appropriate and whether MRD monitoring is being correctly applied.
Can my child access CAR-T for relapsed ALL through CancerFax?
Yes — CancerFax specifically manages paediatric r/r ALL CAR-T access, including Chinese NMPA-approved CD19-directed products at PKUPH and Ruijin Hospital (for patients who have failed or are ineligible for tisagenlecleucel under FDA/EMA labels), and tisagenlecleucel access coordination in countries where it is approved. Eligibility assessment is the first step — contact CancerFax with your child's treatment history and current disease status.
Is proton therapy available for children in Asia?
Yes — Apollo Proton Cancer Centre in Chennai is India's only proton therapy facility with a dedicated paediatric programme. In China, SPHIC Shanghai and several other proton therapy centres treat paediatric cases including medulloblastoma, low-grade glioma, and ependymoma. CancerFax facilitates access to both — and can compare proton therapy costs and clinical protocols between Indian and Chinese centres for specific paediatric diagnoses.
How does CancerFax support families during a paediatric second opinion trip abroad?
CancerFax provides dedicated family support throughout the international second opinion process — including paediatric-friendly accommodation options near the hospital, a bilingual coordinator experienced with paediatric cases, airport transfers for families with young children, and coordination of any sibling accompaniment logistics. We understand that travelling abroad with an ill child is uniquely demanding and work to remove every logistical barrier possible.
More from the Cancer Second Opinion Resource Library
Explore related guides on second opinion centres, CAR-T access, and the facilitation process.
- ↑ Cancer Second Opinion — Complete Guide
- Second Opinions for CAR-T Therapy Eligibility: China vs Western Access
- Second Opinions for Blood Cancers: Ruijin Hospital and Peking University
- Getting a Cancer Second Opinion at Tata Memorial Centre Mumbai
- How CancerFax Facilitates Second Opinions: From First Contact to Delivery
- Telemedicine Cancer Consultations: How to Prepare for a Video Consultation Abroad
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Request a Paediatric Cancer Second Opinion Through CancerFax
CancerFax coordinates paediatric oncology second opinions at leading centres in India and China — managing records preparation, molecular testing review, appointment booking with the relevant paediatric subspecialist, and full logistics support for families travelling internationally.
This content is for informational purposes only and does not constitute medical advice. All paediatric cancer treatment decisions must be made by a qualified paediatric oncologist.